MA44207A - Immunoglobulines conjuguées cys80 - Google Patents

Immunoglobulines conjuguées cys80

Info

Publication number
MA44207A
MA44207A MA044207A MA44207A MA44207A MA 44207 A MA44207 A MA 44207A MA 044207 A MA044207 A MA 044207A MA 44207 A MA44207 A MA 44207A MA 44207 A MA44207 A MA 44207A
Authority
MA
Morocco
Prior art keywords
immunoglobulins
chain variable
cys80
immunoglobulin
light chain
Prior art date
Application number
MA044207A
Other languages
English (en)
Other versions
MA44207B1 (fr
Inventor
Earl Albone
Luigi Grasso
James Bradford Kline
Jared Spidel
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA44207A publication Critical patent/MA44207A/fr
Publication of MA44207B1 publication Critical patent/MA44207B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés de génération d'immunoglobulines conjuguées, le procédé comprenant : le décoiffage d'une cystéine à la position d'acide aminé 80 ("cys80") dans une région variable de chaîne légère d'une immunoglobuline, l'immunoglobuline comprenant une région variable de chaîne lourde et la région variable de chaîne légère ; et la conjugaison d'un composé réactif avec thiol avec cys80, le composé réactif avec thiol comprenant un groupe réactif avec thiol. L'invention concerne en outre des molécules de liaison d'antigène et des procédés de génération de celles-ci, des immunoglobulines ainsi que des molécules d'acide nucléique codant pour les immunoglobulines et des cellules hôtes comprenant les molécules d'acide nucléique, des immunoglobulines conjuguées, et des régions variables de chaîne légère pour utilisation dans une immunoglobuline conjuguée.
MA44207A 2015-06-19 2016-06-17 Immunoglobulines conjuguées cys80 MA44207B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182020P 2015-06-19 2015-06-19
PCT/US2016/038041 WO2016205618A1 (fr) 2015-06-19 2016-06-17 Immunoglobulines conjuguées cys80

Publications (2)

Publication Number Publication Date
MA44207A true MA44207A (fr) 2018-12-26
MA44207B1 MA44207B1 (fr) 2020-11-30

Family

ID=56404289

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44207A MA44207B1 (fr) 2015-06-19 2016-06-17 Immunoglobulines conjuguées cys80

Country Status (32)

Country Link
US (3) US10273310B2 (fr)
EP (2) EP3310816B1 (fr)
JP (2) JP6823606B2 (fr)
KR (1) KR102718129B1 (fr)
CN (1) CN107949575B (fr)
AU (1) AU2016280190B9 (fr)
CA (1) CA2989637C (fr)
CL (1) CL2017003273A1 (fr)
CO (1) CO2017013303A2 (fr)
CY (1) CY1123481T1 (fr)
DK (2) DK3310816T3 (fr)
ES (2) ES2967613T3 (fr)
HR (1) HRP20201489T1 (fr)
HU (2) HUE051315T2 (fr)
IL (1) IL256263B (fr)
LT (1) LT3310816T (fr)
MA (1) MA44207B1 (fr)
MD (1) MD3310816T2 (fr)
MX (1) MX389687B (fr)
MY (1) MY189024A (fr)
PE (1) PE20180498A1 (fr)
PH (2) PH12017502352B1 (fr)
PL (1) PL3310816T3 (fr)
PT (1) PT3310816T (fr)
RS (1) RS60943B1 (fr)
RU (1) RU2756101C2 (fr)
SG (1) SG10201913935RA (fr)
SI (1) SI3310816T1 (fr)
SM (1) SMT202000633T1 (fr)
UA (2) UA129321C2 (fr)
WO (1) WO2016205618A1 (fr)
ZA (2) ZA201708619B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021090062A1 (fr) * 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Conjugués anticorps-médicament d'éribuline dirigés contre la mésothéline et procédés d'utilisation
CN115335406B (zh) * 2020-02-12 2026-01-30 伊莱利利公司 抗体或抗原-结合片段的结晶
AU2021284401A1 (en) 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use
CN112694521B (zh) * 2020-12-02 2023-01-17 杭州百凌生物科技有限公司 一种人工多肽lh、其抗体及在病理检测中的应用
CN120813607A (zh) 2023-02-28 2025-10-17 卫材R&D管理有限公司 抗psma抗体、缀合物和使用方法
TW202602943A (zh) 2024-03-22 2026-01-16 日商衛材R&D企管股份有限公司 抗ｔｒｏｐ２抗體藥物偶聯物及使用方法
WO2026044039A2 (fr) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Anticorps anti-cd73, conjugués et procédés d'utilisation
WO2026044149A2 (fr) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthèse de combinaisons médicament-lieur pour conjugués anticorps-médicament
WO2026071051A1 (fr) * 2024-09-27 2026-04-02 東レ株式会社 Agent réducteur pour éliminer la coiffe d'une immunoglobuline ou d'un fragment de liaison à l'antigène de celle-ci

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05214B1 (et) * 1998-04-28 2009-10-15 Applied Research Systems ARS Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
US6904369B1 (en) * 2000-06-29 2005-06-07 The Trustees Of Columbia University In The City Of New York Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor
US7402409B2 (en) 2003-01-23 2008-07-22 Epitomics, Inc. Cell fusion method
AU2003259718A1 (en) * 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2006017759A2 (fr) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Anticorps fixant le marqueur specifique des cellules endotheliales (tem1) et leurs utilisations
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
AU2008246442B2 (en) * 2007-05-04 2014-07-03 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
KR20170036814A (ko) * 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
BRPI0907046A2 (pt) * 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
DK2265283T3 (da) 2008-03-18 2014-10-20 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
WO2010118203A2 (fr) 2009-04-09 2010-10-14 Morphotek, Inc. Molécules de liaison à l'endosialine
CA2799540A1 (fr) * 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugues modifies par la cysteine
RU2012157167A (ru) * 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Полифункциональные антительные конъюгаты
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
EP3327037B1 (fr) * 2012-08-21 2019-10-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anticorps monoclonaux spécifiques au domaine de la mésothéline et utilisation de ces derniers
HUE045144T2 (hu) * 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions

Also Published As

Publication number Publication date
ES2829251T3 (es) 2021-05-31
KR20180021807A (ko) 2018-03-05
JP2020178717A (ja) 2020-11-05
CY1123481T1 (el) 2022-03-24
DK3310816T3 (da) 2020-10-12
AU2016280190B9 (en) 2022-05-19
MY189024A (en) 2022-01-20
CN107949575B (zh) 2022-03-08
UA129321C2 (uk) 2025-03-19
EP3310816A1 (fr) 2018-04-25
CA2989637A1 (fr) 2016-12-22
MA44207B1 (fr) 2020-11-30
JP7042876B2 (ja) 2022-03-28
PE20180498A1 (es) 2018-03-09
ZA202102093B (en) 2023-03-29
MX389687B (es) 2025-03-20
UA124830C2 (uk) 2021-12-01
PT3310816T (pt) 2020-10-19
EP3310816B1 (fr) 2020-09-09
PH12021551939A1 (en) 2022-05-02
JP6823606B2 (ja) 2021-02-03
RU2017146220A (ru) 2019-07-19
SG10201913935RA (en) 2020-03-30
US20230001004A1 (en) 2023-01-05
RU2017146220A3 (fr) 2019-11-07
HUE051315T2 (hu) 2021-03-01
CA2989637C (fr) 2023-01-10
US11129904B2 (en) 2021-09-28
ES2967613T3 (es) 2024-05-03
US10273310B2 (en) 2019-04-30
AU2016280190B2 (en) 2022-04-28
CO2017013303A2 (es) 2018-03-20
LT3310816T (lt) 2020-11-25
EP3795591A1 (fr) 2021-03-24
DK3795591T3 (da) 2024-01-02
EP3795591B1 (fr) 2023-09-27
MX2017016674A (es) 2018-08-01
HRP20201489T1 (hr) 2020-12-11
ZA201708619B (en) 2022-11-30
IL256263B (en) 2022-06-01
DK3795591T5 (da) 2024-08-19
US20190202933A1 (en) 2019-07-04
HUE064407T2 (hu) 2024-03-28
MD3310816T2 (ro) 2021-01-31
US20160369011A1 (en) 2016-12-22
CL2017003273A1 (es) 2018-12-21
CN107949575A (zh) 2018-04-20
NZ738496A (en) 2023-08-25
WO2016205618A1 (fr) 2016-12-22
IL256263A (en) 2018-02-28
RU2756101C2 (ru) 2021-09-28
PH12017502352B1 (en) 2023-05-26
JP2018526975A (ja) 2018-09-20
BR112017027252A2 (pt) 2018-08-28
HK1252625A1 (en) 2019-05-31
PH12017502352A1 (en) 2018-06-25
PL3310816T3 (pl) 2020-12-14
KR102718129B1 (ko) 2024-10-17
RS60943B1 (sr) 2020-11-30
SMT202000633T1 (it) 2021-01-05
AU2016280190A1 (en) 2018-01-18
SI3310816T1 (sl) 2020-12-31

Similar Documents

Publication Publication Date Title
MA44207A (fr) Immunoglobulines conjuguées cys80
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
NZ739721A (en) Antigen binding constructs to target molecules
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
MA40510A (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
EA201791742A1 (ru) Антитела, направленные против гена-3 активации лимфоцитов (lag-3)
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
EA201491827A1 (ru) Антитела против hla-b*27 и их применение
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MA40972B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3
MX372817B (es) Anticuerpos dirigidos contra la proteína muerte programada-1 (pd-1).
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MX2021001672A (es) Receptor de antigeno quimerico que se une a hla-dr y linfocito t-car.
MX2013002323A (es) Anticuerpos para metaloproteinasa.
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
EA201892063A1 (ru) МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
EA202092981A1 (ru) Антитела к l1cam и их применение
EA202092769A1 (ru) Антитела против cd63, их конъюгаты и применения
MA41666B1 (fr) Anticorps anti-ox40 et leurs utilisations
MA40086A1 (fr) Anticorps anti-vasa et leurs procédés de production et d'utilisation